Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback